**Supplementary File 4: Characteristics of the patient cohort used to generate immuno-histochemical data.**

 **n %**

***Total Samples***  52

***Histology*** Adenocarcinoma 50 96.2%

 Large cell favouring adenocarcinoma 1 1.9%

 Mucinous adenocarcinoma 1 1.9%

***Stage***  IV 36 69.3%

 IIIA 8 15.4%

 IIIB 5 9.6%

 III 1 1.9%

 IIB 1 1.9%

 II 1 1.9%

***Chemotherapy*** Carboplatin/Gemcitabine 28 53.8%

 Carboplatin/Pemetrexed 3 5.8%

 Carboplatin/Pemetrexed +/- Pembrolizumab 4 7.7%

 Carboplatin/Taxol + Bevacizumab 2 3.8%

 Concurrent Carboplatin/Taxol 11 21.2%

 Concurrent Cisplatin/Etoposide 3 5.8%

 Concurrent Carboplatin + Unknown 1 1.9%